Employing the intravesical delivery route to target on the kidney
Abstract
ABSTRACT:
Background and Objective: There is an unmet demand for kidney-targeted non-invasive drug-delivery systems to enhance the therapeutic index and at the same time reduce extrarenal side effects. Here, we performed a proof-of-concept study to evaluate the validity and efficacy of intravesical delivery for kidney targeting in mice.
Methods: Probes with a wide range of molecular sizes were tested for their efficiency to reach the kidney via intravesical delivery in female mice. The therapeutic efficacy and side effects of pazopanib in treating a renal adenocarcinoma were compared between delivery via intravesical route vs. intraperitoneal route. Intravesical delivery of empagliflozin was tested for its action on the proximal tubules. Finally, intrapelvic infusion was examined as another retrograde route for targeting the kidney.
Key findings and limitations: Intravesical infusion was valid for a retrograde delivery of molecules up to 500 kDa to the kidney. Empagliflozin, an antagonist of sodium-glucose cotransporter 2 (SGLT2), could efficiently act on the proximal tubules via the intravesical route, and had an action on glucose excretion. In an orthotopic kidney carcinoma model, intravesical delivery of pazopanib was more efficacious in limiting tumor growth, accompanied with much milder adverse effects on extrarenal organs, compared to a systemic delivery when a same dose was administered. This was due to a higher intrarenal drug concentration achieved and a markedly…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.